Aromatic compounds such as polycyclic aromatic hydrocarbons, arylamines and heterocyclic amines require metabolic activation to form metabolites able to bind to DNA, a process mediated by polymorphic enzymes. We measured aromatic DNA adducts in white blood cells by the 32 P-post-labelling assay in a sample of 296 healthy adults (147 men and 149 women) from five regions of Spain. We also analyzed functional polymorphisms in the metabolic genes CYP1A1, CYP1A2, EPHX1, GSTM1, GSTT1, NAT2 and SULT1A1. A significant increased level of DNA aromatic adducts was found related to the fast oxidation-hydrolysis phenotype defined by the polymorphism I462V in CYP1A1, the allele A in IVS12154C>A of CYP1A2 and the combination Tyrosine-Arginine for Y113H and H139R of EPHX1. Geometric means (adducts per 10 29 normal nucleotides) were 2.17, 4.04 and 6.30 for slow, normal and fast phenotypes, respectively (P-trend 5 0.01). Slow acetylation by NAT2 was associated with a significant decrease in adduct level; subjects with slow alleles Ã 5A and Ã 7A/B had in average 1.56 3 10 29 adducts, as compared with 5.60 for those with normal NAT2 activity (P-value 5 0.01). No association was seen with polymorphisms of other metabolic genes such as GSTM1, GSTT1 or SULT1A1. We concluded that the metabolic pathways of oxidation, hydrolysis and acetylation are relevant to the formation of bulky DNA adducts. This could suggest a potential involvement of aromatic compounds in the formation of such adducts; however, given lack of specificity of the post-labeling assay, a firm conclusion cannot be drawn.
Introduction
Chemical carcinogenesis assumes that exposure to a genotoxic compound results in damage to the structural integrity of DNA typically involving the covalent binding to DNA, referred to as carcinogen-DNA adduct formation (1) . Studies in animal models have shown that dose-response curves for chemical exposure, DNA adduct formation, mutagenesis and rates of tumour development are closely correlated. This supports the notion that DNA adducts play a significant role in the carcinogenic process, and therefore represent a measure for exposure as well as cancer risk (2) . Several techniques have been used to measure DNA adducts in human tissues. The 32 P-post-labelling assay has been widely applied because of its high sensitivity and the requirement for only microgram amounts of DNA. 32 P-post-labelling typically detects a mixture of adducts often referred to as aromatic or bulky adducts (2) . Several groups of aromatic compounds may be relevant to human carcinogenesis, mainly the ubiquitous polycyclic aromatic hydrocarbons (PAHs) formed during the incomplete combustion of organic material, but also the aromatic amines (AA) or heterocyclic amines (HA). Environmental sources of PAH include industrial and urban air pollution, tobacco smoke and diet, the main source of exposure in non-smokers who are not exposed through their occupations (1, 3) . AAs are occupational contaminants mainly in the dyestuff and rubber industry, whereas HA are formed during cooking foods in the presence of creatinine, mostly meat and fish (1, 4) .
As many human carcinogens, these compounds are chemically inert and metabolic activation is required to form electrophilic DNAdamaging metabolites. Activation of PAH involves the formation of bay-region diol epoxides; the first step of this process is oxidation by cytochrome P450 (CYP) enzymes, mainly CYP1A1 and CYP1A2, to form epoxides. Then hydrolysis by microsomal epoxide hydrolase (EPHX) 1 forms intermediate transdihydrodiols, which are further converted by CYP enzymes to reactive diol epoxides. Intermediate metabolites as well as diol epoxides can be detoxified through conjugation with glutathione by glutathione S-transferases (GSTs), mainly GSTM1 and GSTT1 (1, 3) . An alternative pathway of PAH activation is conjugation with sulfate of hydroxylated or tetrol derivatives catalyzed by sulphotransferases (SULTs) (5) . N-hydroxylation mediated by CYP1A2 is the initial step of activation of AA and HA, followed by O-esterification catalyzed by N-acetyl-transferases (NATs) resulting in a highly reactive metabolite by the generation of arylnitrenium ions. O-esterification of HA may be achieved as well by the formation of sulfoxy esters catalyzed by SULTs (3, 4) .
In humans, most metabolic enzymes are highly polymorphic; the main single-nucleotide polymorphisms (SNPs) identified in the genes encoding such enzymes as well as their effects on enzyme function are summarized in Table I . Among the SNPs described for CYP1A1, three variants (m1, m2 and m4) are often reported in Caucassian populations (3) . Initially, 1188 bp 3# of STP C.T (m1) was associated with the highly inducible phenotype, although no influence on enzyme activity was found in some studies (3, 6) . The substitution of valine for isoleucine I462V (m2) results in an $2-fold increase in the enzyme activity (3, 7) , whereas the functional significance of T461N (m4) is uncertain (7) . Two mutations associated with inducibility have been described in CYP1A2; the allele C of IVS1À154C.A, relatively frequent in several ethnic groups, shows decreased caffeine metabolism only among smokers (8) , whereas the variant A of À3859A.G expressed a low activity enzyme among Japanese smokers (9) but nothing could be concluded among Caucassians owing to its low population frequency (8) . The gene EPHX1 has two known functional polymorphisms (Y113H and H139R) in the coding region (10) ; in vitro activity of the protein with histidine at codon 113 is reduced $40%, whereas the form with arginine at codon 139 increased $25% (11) . Three SNPs in NAT2 (L161L, R197Q and G286E) are used to assign the alleles NAT2 Ã 5, NAT2 Ã 6 and NAT2 Ã 7, respectively (12) . The absence of any of these substitutions is considered as the wild-type (NAT2 Ã 4), although it is not the most common allele in Caucasians populations; subjects with any of the above-mentioned substitutions are defined as slow acetylators (12, 13) . Concerning SULT1A1, R213H is a SNP relatively common among Caucasians; the variant with histidine in position 213 is related to lower activity and lower thermal stability of the enzyme (14) . Finally, deletion of both GSTM1 and GSTT1 is relatively common in Caucasians; subjects homozygous for a null allele lack enzymatic activity and are assumed to be detoxication deficient (15) .
The role of variation in metabolizing enzymes as potential susceptibility factors has been mainly addressed through the association between SNPs in metabolic genes and several tumour sites, whereas not many studies focused on the dependence of DNA adducts on genotype (1, 3) . We present the results of a study based upon a sample of healthy adults non-selected on the basis of previous exposure, with the aim of analyzing the relationship between the level of aromatic DNA adducts in white blood cell (WBC) and functional SNPs in CYP1A1, CYP1A2, EPHX1, GSTM1, GSTT1, NAT2 and SULT1A1. Furthermore, we also addressed the dependence of adducts level on the imputed phenotype and metabolic pathways derived from these genotypes.
Materials and methods

Subjects and study design
The study subjects were selected from the Spanish cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC) study (16) . The EPIC-Spain cohort included 41 438 healthy volunteers aged 29-69 years recruited between 1992 and 1996 in five regions in Spain: three from the north (Asturias, Guipúzcoa and Navarra) and two from the south (Granada and Murcia). Information on usual diet and lifestyle factors, anthropometric measurements and a 20 ml blood sample were obtained from each subject at baseline. Blood samples were divided into 0.5 ml aliquots of plasma, serum, concentrated red blood cells and buffy coat and stored in liquid nitrogen tanks at À196°C. For the current study, 300 subjects (60 from each center) aged 35-64 years at recruitment were randomly selected by stratified sampling according to the age-sex structure of the Spanish population (http://wwwinees/inebmenu/ indicehtm.). Biological material was not available for four participants, thus the study population is composed of 296 subjects.
DNA extraction and purification DNA from WBC was extracted from 100-150 ll buffy coats. It was purified by digestion with ribonuclease A, ribonuclease T1 and proteinase K and extracted with saturated phenol, phenol:chloroform:isoamyl alcohol (25:24:1) and ethanol precipitation (17) . DNA was then dissolved in distilled water, and its concentration and purity was measured by a Beckam DU 800 spectrophotometer. The coded DNA was stored at À80°C until laboratory analysis.
DNA adducts determination:
32 P-DNA post-labelling technique DNA adducts were analyzed using the nuclease P1 modification of the 32 P-DNA post-labelling technique (18, 19) . Coded DNA samples (1-5 lg) were initially digested to normal and adducted 3#-mononucleotides with micrococcal nuclease (0.46 U) and spleen phosphodiesterase (0.0174 U). After treatment of samples with 5 lg nuclease P1 for 30 min at 37°C, the hydrolyzate enriched in adducted nucleotides were then labeled by incubation with 25-50 lCi carrierfree [c- 32 P]adenosine triphosphate (3000 Ci/mM) and 10 U T4 polynucleotide kinase. Detection of bulky DNA adducts was carried out by multidirectional polyethileineimine-cellulose thin-layer chromatography. Plates were first developed overnight using 1 M sodium phosphate (pH 6.8) then the resolution of the bulky DNA adducts was achieved with a two-dimensional chromatography (15) using 4 M lithium formate, 7.5 M urea (pH 3.5), 0.65 M lithium chloride, 0.45 M Tris base and 7.7 M urea (pH 8.0). The plates were finally developed overnight using 1.7 M sodium phosphate (pH 5.0). Detection and quantification of 32 P-labeled DNA adducts and total nucleotides were performed by storage phosphor imaging techniques employing imaging screens from Molecular Dynamics (Sunnyvale, CA). After exposure, the screens were immediately scanned using a Typhoon 9210 (Amersham, Buckinghamshire, UK). Data were processed with ImageQuant (v.5.0) from Molecular Dynamics. The levels of DNA adducts were expressed as relative adduct labeling screen response (volume) in adducted nucleotides/screen response (volume) in total nucleotides (20) .
All analyses were carried out blindly, and a standard was routinely included in the analysis; the standard was an adducted DNA from livers of mice intraperitoneal treated with 0.5 mg benzo(a)pyrene (BaP) from a previous interlaboratory trial (19) . The average level of adducts in the BaP-DNA mouse liver samples was 8.5 adducts per 10 8 nucleotides by mass spectrometry and 11.4 adducts per 10 8 nucleotides by 32 P-post-labelling. Since the assay efficiency can vary between experiments, we have corrected for run-to-run variation. The detection limit was 0.1 adduct per 10 9 normal nucleotides, as reported (21) . A second aliquot of 1-5 lg of DNA was used to carry out a second independent measurement of adducts by the same assay in 41 of 296 subjects; the estimated intraclass correlation coefficient was 0.98 indicating a high reliability of the measurement (22) .
Genotyping
SNPs genotyping was performed in a LightCycler TM 2.0 instrument (Roche Diagnostics, Mannheim, Germany) by melting curve analysis of a fluorescently labeled sensor probe specific for each polymerase chain reaction-amplified variant. The analysis of CYP1A1, CYP1A2, EPHX1 and NAT2 polymorphisms was as described previously (23, 24) . SULT1A1 R213H was genotyped with essentially the same methodology using primers and hybridization probes designed and synthesized by TIB-MOLBIOL (Berlin, Germany), which can be provided by the authors upon request. The silent mutation in Ex2 þ 487C.T is found in the same haplotype ( Ã 5A) as the T-to-C substitution at Ex2 þ 347 with the aminoacid replacement I114T.
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Analysis of the GSTM1 and GSTT1 null alleles was also performed in the LightCycler 2.0 instrument by melting curve analysis of the fragments amplified in a capillary multiplex polymerase chain reaction that contained specific primers for the amplification of GSTM1, GSTT1 and BCL2 (used as an amplification control) fragments and the LightCycler TM Fast Start DNA Master SYBR Green I kit (Roche Diagnostics). With the exception of the reverse primer for the GSTT1 fragment that was modified to obtain a shorter amplification product of 257 bp, the primers used to amplify the GSTM1 (219 bp), GSTT1 (257 bp) and BCL2 (154 bp) fragments had been described previously (25) .
Genes have been named according to the Human Genome Organisation Gene Nomenclature Committee (http://www.genenames.org/guidelines.html). Metabolic gene allele nomenclature follows published recommendations (26) . Polymorphisms are identified according to the SNP500Cancer Database (http://snp500cancer.nci.nih.gov) and the accession number from the National Center for Biotechnology Information database of SNPs (http://www.ncbi.nlm. nih.gov/projects/SNP/).
Imputed phenotypes
Polymorphisms in the same or different genes were merged into one singlevariable based upon the known effect on enzymatic function and the genotype analysis from our own study (see below). Three metabolic pathways were considered, namely oxidation, hydrolysis and acetylation; these three pathways were used to define five imputed phenotypes. Increased oxidation was assigned to subjects carrying the allele G for I462V of CYP1A1 and allele A for IVS1À 154C.A in CYP1A2; low oxidation was assigned to homozygous AA for I462V of CYP1A1 and homozygous CC for IVS1À154C.A; subjects carrying the homozygous AA for I462V and allele A for IVS1À154C.A were considered to have an intermediate oxidative activity termed as normal oxidation. The imputed phenotype for hydrolysis was defined as follows: low activity for homozygous CC in Y113H (histidine) with allele A in H139R; high activity for homozygous GG in H139R (arginine) with allele T in Y133H and normal activity for those carrying the allele T for Y113H and allele A for H139R. Three subjects carrying the homozygous genotypes CC and GG for Y113H and H139R, respectively, were excluded from this analysis because its simultaneous effect on the enzymatic activity is unknown. Those with the NAT2 homozygous genotype CC for Ã 5A and GG for Ã 7A/B were considered as having normal NAT2 activity; moderately slow activity was assigned to subjects with allele T for Ã 5A keeping the wild-type CC for Ã 7A/B, and very slow acetylation was assigned to subjects with allele A for Ã 7A/B whatever the genotype for Ã 5A. Since CYP-mediated oxidation and hydrolysis by EPHX1 are supposed to act in the same pathway, an oxidation-hydrolysis phenotype was created by combining both phenotypes as follows: normal, for normal activity of both oxidation and hydrolysis; low, for low activity of both or low activity of one phenotype and normal for the other and high, for high activity of both or high activity for one phenotype and normal for the other; one subject with high oxidation and low hydrolysis and two subjects with low oxidation and high hydrolysis were excluded. In a similar way, CYP1A2-mediated oxidation and acetylation supposed to act in the same pathway were combined to form an oxidation-acetylation phenotype. Concerning CYP1A2, those carrying the C allele IVS1À154C.A were considered as having slow activity, as compared with homozygous AA, considered normal; thus, the oxidation-acetylation phenotype was defined as follows: normal, for normal activity of both phenotypes; moderately slow, for normal oxidation and moderately slow acetylation or slow oxidation and normal acetylation; slow, for slow oxidation and moderately slow acetylation and very slow, for slow oxidation and very slow acetylation; five subjects with normal oxidation and very slow acetylation were excluded.
Statistical analysis
Genotype frequencies were computed for each polymorphism and departure from Hardy-Weinberg equilibrium (HWE) was assessed by means of an exact test; pairwise linkage disequilibrium (LD) was also tested for SNPs within the same gene (27) . The level of DNA adducts was expressed as adducted nucleotides per 10 9 normal nucleotides. Negative samples (those below 0.1 adduct per 10 9 normal nucleotides, the threshold of detection of the technique) were assigned a value of 0.05. The distribution of DNA adducts was right-skewed and the variable was transformed using natural logarithms. All the results for adduct levels are expressed as geometric mean with the corresponding 95% confidence intervals (CIs). After log transformation, the data were normalized; the Shapiro-Wilk W-test (28) was non-significant (P 5 0.39) after exclusion of subjects with values below the detection limit. However, the analyses were repeated by means of non-parametric methods using the Kruskal-Wallis test or the Cuzick's extension of the rank-sum test for trend test across ordered categories (28) . Since the results with both approaches gave the same conclusions, only those from the parametric analyses are shown.
Association of each SNP with DNA adduct levels was tested by one-way analysis of variance (28), comparing means in the three genotypes (codominant model) or grouping homozygotes and heterozygotes (dominant or recessive models). Linear regression (28) was used to assess the additive model, assuming a linear relationship between the DNA adducts level (the dependent variable) and genotype, the independent variable denoted by 0 represents the wild-type (common homozygote), 1 represents the heterozygotes and 2 represents the rare homozygote.
Linear regression was used as well to assess the relationship of multiple SNPs and imputed phenotypes with DNA adducts. Multipoint SNPs association analysis (27) was carried out by including several SNPs in the regression model to take into account their joint distribution. However, when strong LD was present, haplotype-based methods were used to try to capture its correlation structure. Haplotype analysis was achieved by estimating haplotype frequencies and comparing the mean DNA adducts level of each haplotype with the most common haplotype, taken as the reference category (29) . Regarding imputed phenotypes, the t-test was used to compare the mean of high or low enzymatic activity with the mean of the normal phenotype (reference category). A trend test was carried out by assessing the significance of the regression coefficient of a variable coded as 0 for normal, À1 for low and þ1 for high activity for oxidation, hydrolysis and oxidation-hydrolysis or 0 for normal, 1 for moderately slow and 2 for very slow acetylation (28) . Finally, interaction between two genes or between a gene and an imputed phenotype was assessed by comparing the likelihood of the model with the corresponding interaction terms and the model containing terms for the main effects only. The likelihood-ratio statistic typically has a Chi-square distribution with degrees of freedom equal to the number of additional parameters (27) .
Results
Results were available for 296 subjects (147 men and 149 women), aged 35-64 years with mean age of 49 years at the time of recruitment and blood extraction (in both genders). They were residents in three regions from the North of Spain (60%) and two from the South (40%). Overall 74 (25%) of subjects were current smokers, 48 (16%) were former smokers and 174 (59%) had never smoked; furthermore, 13% (38 subjects) had ever been employed in occupations involving potential exposure to PAH. Aromatic DNA adducts were detected in 255 of 296 samples (86%); the geometric mean (95% CI) was 4.04 (3.26, 4.97) adducts per 10 9 normal nucleotides, whereas the arithmetic mean was 8.30 (7.54, 9.05). Further details of lifestyle features of our population and its relationship with adduct levels have been reported elsewhere (Ibáñez,R., Peluso,M., Munnia,A., Piro,S., González,C.A., Amiano,P., Tormo,M.T., Ardanaz,E., Barricarte,A., Berenguer,A., Chirlaque,M.D., Dorronsoro,M., Jakszyn,P., Larrañaga,N., Martínez,C., Navarro,C., Quirós,J.R., Sánchez,M.J. and Agudo,A submitted for publication).
The genotype distribution of the polymorphisms analyzed with the corresponding geometric mean of adducts level is shown in Table II . The genotype frequencies of all but two SNPs (I462V, T461N in CYP1A1) were conformed to Hardy-Weinberg expectations. Both have a proportion of homozygotes higher than expected according to HWE (1% versus 0.23% for I462V, 1% versus 0.18% for T461N), with a relative deficit of heterozygotes (7.5% versus 9% m2, 6.4% versus 8% m4). There was remarkable LD between m1 and m2 of CYP1A1 as well as the two SNPs analyzed in CYP1A2; the allele Ã 5A in NAT2 was also in strong LD both with Ã 6A and Ã 7A/B. A significant LD, although less evident, was observed between I462V and T461N in CYP1A1 and between Y113H and H139R in EPHX1. Regarding the differences in adduct levels by genotype, only the presence of allele A in Ã 7A/B of NAT2 was significantly associated with lower adduct level (geometric mean 1.56 as compared with 4.24 of GG, P-value 5 0.04). Other variants seemed to be associated with increased (I462V, H139R) or decreased ( Ã 5A, IVS1À154C.A) adduct levels, but none of them was statistically significant.
The joint effects of SNPs within CYP1A1 and NAT2 were assessed by means of haplotype analysis (Table III) . Seven haplotypes were found for CYP1A1; compared with the wild-type, no differences in adduct levels were seen for haplotypes showing only the variants corresponding to m1 (haplotype 2) or m4 (haplotype 4); however, the haplotype 3, with the variant alleles both for m1 and m2 had an increased adduct level, although the difference was non-significant (P-value 5 0.11). Haplotypes 6 (variant in the three SNPs) and 7 (variant alleles for m1 and m4) were associated with a strong and A.Agudo et al. The P-trend corresponds to the significance of the regression coefficient of a variable coded as 0 for the wild-type, 1 for the heterozygous variant and 2 for the homozygous variant (additive model).
Aromatic DNA adducts and polymorphisms in metabolic genes in healthy adults significant decrease in adduct level, but they are very rare in the population (frequency ,1%) and these results must be taken with caution. Regarding NAT2, four of seven haplotypes had frequencies .1%; the estimated frequency for the wild-type (haplotype 3) was 21%. Haplotypes 1, 2 and 4 corresponding, respectively, to slow acetylator alleles Ã 5A, Ã 6A and Ã 7A/B had lower levels of adducts as compared with haplotype 3, but none of the differences was statistically significant. The simultaneous effect of several SNPs was also addressed by means of multipoint association analysis (results not shown). Polymorphisms m1 and m2 of CYP1A1 were strongly correlated; actually all subjects with the variant G of m2 had the variant C for m1, but when they were analyzed together in a model only those with the variant m2 had a higher level of adducts. On the other hand, m2 and m4 had some effect, although in opposite direction; since the functional significance of m4 is uncertain, only m2 (I462V) was considered in the phenotype analysis. Regarding NAT2, when the three SNPs were analyzed together, only the allele Ã 7A/B was statistically significant. The dominant model of Ã 5A was associated with lower level of adducts with P-value 5 0.11, and no effect was observed for Ã 6A (results not shown); thus, only alleles Ã 7A/B and Ã 5A were used to assess acetylation.
The relationship of adduct levels with imputed phenotypes of oxidation, hydrolysis and acetylation is shown in Table IV . There was a clear trend to a higher level of adducts with oxidative activity as well as with EPHX-mediated hydrolysis, although they did not reach significance. However, when they were considered together as oxidationhydrolysis pathway, a significant trend appeared (P-trend 5 0.01). A clear trend was observed between decreasing levels of adduct and slower acetylation activity (P-trend 5 0.018); furthermore, the very slow acetylators (defined by the allele A in Ã 7A/B) have a significantly lower level of adducts as compared with subjects with normal activity (geometric mean 1.56 and 5.60, respectively, P-value 5 0.016). There was also a trend between lower levels of adducts and slower oxidationacetylation activity, although the difference between the extreme categories was no significant. An alternative way to deal with acetylation would be the simple summation of slow genotypes, but this would ignore the fact that individual SNPs may induce slow phenotypes by different mechanisms and different degrees of modification of the enzymatic activity (13) . Furthermore, it would not take into account the strong LD between SNPs in our population. Only 11 (4%) subjects had the wild-type genotype, 170 (59%) carried one slow SNP and 108 (37%) had two slow SNPs; none of them had the three slow genotypes.
The corresponding geometric mean (95% CI) were 6.31 (2.09, 19.0), 4.31 (3.25, 5.70) and 3.34 (2.34, 4.75) with a P-trend 5 0.17; none of the pairwise differences were significant. Thus, combining Ã 5A and Ã 7A/B was considered better to account for the acetylation phenotype that the summation approach in our population.
Since the subject's genotype is determined by an apparently random process, the genotypes distribution may be considered unrelated to environmental and behavioral factors related to adduct level. However, we fit models for adduct levels as a function of each phenotype adjusted by sex, age, center, tobacco smoking, occupation, body mass index, energy intake, alcohol and the consumption of cereals, meat, fish, milk and dairy products. Results from the multivariate model were very similar to those observed using the univariate approach. Furthermore, to prevent possible residual confounding due to effect of relevant exposures (i.e. tobacco smoking) that may account for the observed differences, we carried out a separate analysis among the 174 never smokers. The geometric means (95% CI) of adduct levels for the oxidation-hydrolysis pathway were 2.33 (1.44, 4.74) for low, 4.72 (3.46, 6.46) for normal and 5.80 (2.89, 11.6) for high activity (P-trend 5 0.24). Regarding the oxidation-acetylation phenotype, the adduct levels were 5.76 (2.86, 11.7) for normal, 5.51 (3.70, 8.22 ) for moderately slow, 3.40 (2.19, 5.29) for slow and 2.83 (0.70, 11.6) for very slow activity (P-trend 5 0.054). The pattern of adduct levels among non-smokers for the main imputed phenotypes is quite similar to the one seen in the whole sample, suggesting that the observed differences are not driven by exposure due to smoking.
Finally, we explored the effect of GSTM1 and GSTT1 activity on the adducts level, according to the oxidation-hydrolysis phenotype in order to assess whether reduced detoxification owing to lacking of the enzyme because a null genotype vary at different levels of activation (Figure 1) . The trend for increased adduct level was evident either when GSTM1 or GSTT1 were present or deleted; however, the potential detoxifying effect of GSTs varied at different levels of oxidationhydrolysis activity. For GSTM1, the lack of detoxification due to the absence of the enzyme (null genotype of the gene) translated into an increased level of adducts only among subjects with high oxidativehydrolytic phenotype, while the lower detoxifying effect of GSTT1 was associated with increased level of adducts essentially among subjects with low oxidation-hydrolysis activity. However, given the small number of subjects the differences were not significant. There were no significant interactions between the oxidativehydrolytic pathway and GSTM1 or GSTT1 activity. We also explored Difference between the mean DNA adducts level of each haplotype and the mean of the reference category; DNA adducts level expressed as the natural logarithm of the number of adducts per 10 9 normal nucleotides. b By default, the most common haplotype is taken as the reference category. However, for NAT2 the haplotype corresponding to the normal activity of the enzyme is haplotype 3 (CGG). The alleles involving slow acetylation are T for Ã 5A and allele A both for Ã 6A and Ã 7A/B.
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the combined effect of SULT1A1 activity with the CYP1A2-mediated oxidation or with the acetylator phenotype since they are though to act in the metabolism of HA; there was no effect on the adduct levels of any of such combinations (results not shown). Gene-gene interaction between GSTM1 and GSTT1 was no significant.
Discussion
We found an increased level of DNA aromatic adducts in WBC from healthy adults in Spain related to higher oxidation mediated by CYP enzymes combined with higher activity of microsomal EPHX. In our population, the high oxidative activity was mainly determined by the presence of the I462V in CYP1A1 and the allele A in IVS1À154C.A of CYP1A2. The hydrolase activity is related to Y113H and H139R in EPHX1; the isoenzyme with histidine in both codons shows lower activity while the protein carrying the combination tyrosine-arginine is the fast isoform. Furthermore, the slow acetylator phenotype determined by alleles Ã 5A and Ã 7A/B in NAT2 as well as its combination with the allele C in IVS1À154C.A of CYP1A2 to produce a slow oxidation-acetylation phenotype were associated with a significant decrease in the level of adducts. No association was seen with single SNPs of the above-mentioned genes or with other metabolic genes such as GSTM1, GSTT1 or SULT1A.
The oxidation-hydrolysis pathway is thought to be relevant in the activation of PAHs, but the role of CYP1A2 and NAT2 suggests the potential involvement of other compounds. We measured DNA adducts by 32 P-post-labelling; studies in settings with high PAH exposure found a positive relationship between adducts measured by such method with levels of specific PAH adduct as measured by specific techniques (30) . The nuclease P1 version of the 32 P-post-labelling technique is generally used to analyze the formation of adducts induced from PAHs such as BaP. However, this assay is also effective for the detection of DNA adducts induced from different hydroxyarylamines; actually a number of DNA adduct standards formed by N-hydroxyderivatives of several HA and AA have been analyzed in our laboratory using the nuclease P1 version of the 32 P-post-labelling assay (18, 19) . On the basis of our results, we could expect that at least a part of DNA adducts detected in leukocytes is produced from aromatic amines that are resistant to the 3#-dephosphorylating action of nuclease P1, i.e. 2-acetylaminofluorene, 2-acetylaminophenanthrene, methyl-4-azoaminophenyl, 2-aminophenanthrene and methyl-4-azoaminobenzene (31) . Most of the epidemiological evidence on these chemical carcinogens arises from groups of subjects with high exposure linked to occupation or tobacco smoking, while our study rather reflects the effect of chronic exposure in general population. On the other hand, we measured adducts in DNA from peripheral WBC; even though WBC are not necessarily the most sensitive cells for DNA adduct formation, some results suggest that they might reflect adduct levels in relevant target organs (32) . Furthermore, as a measure of exposure, WBC-DNA adducts have the advantage of accounting for all exposure routes, including inhalation, ingestion and dermal absorption (32) .
Several studies have analyzed the effect of SNPs of metabolic genes on adducts measured by 32 P-post-labelling in DNA from peripheral WBC, either leukocytes or lymphocytes (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . They were carried out in Caucasian populations with subjects not selected on the basis of specific exposure; some used groups occupationally exposed or heavy smokers, but they always included a control (non-exposed) group. GSTM1 was the gene most commonly analyzed; the null genotype was associated with significantly higher level of adducts in six studies (33-35,41,43,45) of fifteen (33-48) , whereas no association was found with the deletion of GSTT1 in eight studies (33-35,37-41) . A (AA/AG) for H139R; low, homozygous CC (histidine) for Y113H and allele A (AA/AG) for H139R and high, allele T (TT/TC) for Y113H and homozygous GG (arginine) for H139R; 3 subjects homozygous CC for Y113H and GG for H139R were excluded. Oxidation-hydrolysis: normal, normal activity of both phenotypes (oxidation, hydrolysis); low, low activity of both or low activity for one phenotype and normal for the other and high, high activity of both or high activity for one phenotype and normal for the other; one subject with high oxidation and low hydrolysis, and two subjects with low oxidation and high hydrolysis were excluded. Acetylation (NAT2): normal, homozygous CC for Ã 5A and GG for Ã 7A/B; moderately slow, allele T (CT/TT) for Ã 5A and GG for Ã 7A/B and very slow, allele A (GA/AA) for Ã 7A/B whatever the genotype for Ã 5A. Oxidation-Acetylation: normal, normal activity of both phenotypes (CYP1A2-oxidation, acetylation); moderately slow, normal oxidation and moderately slow acetylation or slow oxidation and normal acetylation; slow, slow oxidation and moderately slow acetylation and very slow, slow oxidation and very slow acetylation; five subjects with normal oxidation and very slow acetylation were excluded. b The P-values correspond to the t-test comparing the mean of each phenotype for high or low activity with the mean of the normal phenotype (reference category). The P-trend corresponds to the significance of the regression coefficient of a variable coded as 0 for normal, À1 for low and þ1 for high activity phenotypes for oxidation, hydrolysis and oxidation-hydrolysis, as 0 for normal, 1 for slow (moderate) and 2 for very slow acetylation or as 0 for normal, 1 for slow (moderate) and 2 for slow, and 3 for very slow oxidation-acetylation. d Geometric means (95% CI) adjusted for sex, age, center, tobacco smoking, occupations with potential PAH exposure, body mass index, total caloric intake and the dietary consumption of cereals, meat, fish, milk and dairy products, vegetables, fruit and alcohol.
Aromatic DNA adducts and polymorphisms in metabolic genes in healthy adults Regarding CYP1A1, the variant 1188 bp 3# of STP C.T (m1) was associated with increased level of DNA adducts in two studies (34, 36) of nine (33, 34, 36, (38) (39) (40) 43, 47, 48) , while I462V was related with increased adduct level in two studies (36, 43) and no associated in four (40, 42, 45, 47) . No association was found with DNA adducts in the only study looking at the SNP in intron 1 of CYP1A2 (35), as well as in any of the four studies addressing the two common polymorphisms of EPHX1 (33) (34) (35) 37) . Slow acetylation assessed by the presence of at least two of the alleles Ã 5A, Ã 6A or Ã 7A was unrelated with adduct level in four studies (33, 35, 38, 46) and positively associated in two (44, 45) , although the latter did not reach statistical significance (P-value 5 0.06). A few studies addressed the combined effect of SNPs in more than one gene; one study in the Netherlands (35) reported a higher level of adducts for subjects with GSTM1 null genotype, low activity variant of Y113H in EPHX1 and less efficient GPX1 activity; the latter is also though to be involved in PAH detoxification. Another Dutch study (41) found a significant increased adducts level for subjects lacking GSTT1 and slow acetylation (NAT2) as compared with fast acetylators with GSTT1. A Greek study reported an increased level of adducts for subjects carrying mutation m1 in CYP1A1, fast genotype for H139R in EPHX1 and null GSTM1 genotype (37) . Finally, one study in Poland (42) addressed the combined effect of I462V in CYP1A1 and deletion of GSTM1 but no association was found. However, studies that used more specific methods such as high-performance liquid chromatography with fluorescence detection consistently showed that subjects with either m1 or m2 in CYP1A1 and GSTM1 null have a higher level BaP diol-epoxide adducts (3).
Our results tend to agree with previous works regarding the potential role of 1188 bp 3# of STP C.T and mainly I462V as modulators of oxidative activity of CYP1A1 and subsequent increased adduct formation. Regarding CYP1A2, although the SNP in intron 1 has shown to affect inducibility among smokers, most studies have been unable to decipher an effect in the general population (49) . Thus, our results concerning intron 1 polymorphism of CYP1A2 and adduct levels should be taken with caution. On the other hand, previous studies seem to point to a prominent role of GSTM1 not observed in our population. Although GST enzymes are thought to be involved mainly in detoxification, recent evidence points to the ability of these enzymes to produce reactive glutathione conjugates of some chemicals such as dichloroethane and trichloroethylene (15) . Furthermore, the activity of some enzymes does not only depend on the genotype but may change as a consequence of induction by chemicals or by other enzymes. A high inducibility of CYP1A1 was found associated with GSTM1 null genotype, whereas the presence of at least one GSTM1 allele was related to only low levels of induction (50); this could explain the effect on adduct formation at high levels of oxidationhydrolysis pathway among our GSTM1 null subjects (Figure 1 ). In contrast, the null genotype of GSTT1 was associated with higher adduct level mainly among subjects with low oxidative-hydrolysis phenotype. Regarding NAT2, an Italian study (44) reported a strong association between adduct formation and slow acetylation, while our slow acetylators showed decreased adduct levels. The Italian study was mainly based upon subjects with bladder cancer, and thus they might have a relatively high exposure to aromatic amines. It is well known that NAT activity may be substrate-specific; while N-acetylation has detoxifying effect for AA, O-acetylation is seen as an important step in the activation of HA (12, 13) . It could be that in our population dietary exposure to HA be more relevant than exposure to arylamines.
The distribution of genotype polymorphisms I462V and T461N in CYP1A1 were different from the expected according to allelic frequency under HWE. Deviations from HWE can be due to mixture of individuals from heterogenous background; all subjects in our study were recruited in Spain, almost all of them Caucasians, so that our population may be considered homogenous. Furthermore, the observed prevalences of most genotypes were similar to the frequencies reported in other Caucasian populations (51) . Hardy-Weinberg disequilibrium could also result from genotyping errors; independent genotyping was carried out in a subsample of 25-30 subjects as quality control. There was 100% agreement in the two SNPs lacking HWE, namely I462V and T461N in CYP1A1, while non-concordant results were observed in one subject for Ã 6A in NAT2, one subject for IVS1À154C.A in CYP1A2 and another for Y113H of EPHX1. When HWE is primarily tested as a data quality check only loci that deviate from HWE at significance level a , 0.001 or 0.0001 are usually discarded (29) . Therefore, since deviation in our study was rather modest, we decided to include both SNPs in the analysis.
Further limitations in the interpretation of our results refer to the actual composition of bulky adducts and the complex metabolism of chemicals involved in adducts formation. The 32 P-post-labelling is unable to determine the structure of the labeled adducts, but even 9 normal nucleotides (geometric mean) in 273 subjects according to oxidation and hydrolysis phenotype and GSTM1 (A) or GSTT1 (B) activity. GSTM1 and GSTT1 activity defined, respectively, by the presence or deletion of genes GSTM1 and GSTT1. Oxidative activity defined by allele G for the SNP I462V of CYP1A1 (high activity) or homozygous CC for IVS1À154C.A of CYP1A2 (low activity). Hydrolytic activity defined by two SNPs of EPHX1: homozygous CC for Y113H (low activity) or homozygous GG for H139R (high activity). Oxidationhydrolysis activity is determined by combination of both phenotypes as follows: normal, normal activity of both; low, low activity of both or low activity for one phenotype and normal for the other; high, high activity of both or high activity for one phenotype and normal for the other. Trend for increasing DNA adducts with oxidation-hydrolysis activity was significant for subjects with GSTM1 null genotype (P-trend 5 0.027) and GSTT1 present (P-trend , 0.001). Differences in adduct levels by GSTM1 or GSTT1 genotype (present versus null) were no significant within each level of oxidation-hydrolysis. No significant interaction (likelihood-ratio test) of oxidation-hydrolysis phenotype with GSTM1 (P-value 5 0.75) or GSTT1 (P-value 5 0.74).
A. Agudo et al. when a specific compounds is identified there is limited knowledge of their precise mechanisms of activation, and often not all relevant genes involved in the metabolic pathway are included. For instance, other important polymorphic metabolic genes such as nicotinamide quinone oxireductase 1 (NQO1) or other genes from the GST family such as GSTP1 and GSTA1 (15, 52) could probably lead to the formation of adducts. Finally, the amount of DNA adducts are not only the result of exposure but also of unrepaired DNA damage by chemical carcinogens (2) . The normal function of DNA repair enzymes plays a critical role, and SNPs have been found in nearly all human DNA repair genes. A positive relationship has been reported between the level of adducts in WBC and risk alleles in genes involved in the repair of bulky DNA adducts (53) .
In conclusion, a pathway defined by the enhanced oxidation related to SNPs I462V in CYP1A1 and IVS1À154C.A in CYP1A2, and high hydrolase activity of EPHX1 due to fast variants Y113H and H139R, is associated with increased DNA adducts in WBC of healthy Spanish adults. On the other hand, decreased adduct level was associated both with slow acetylation by NAT2 related to alleles Ã 5A and Ã 7A/B and its combination with slow CYP1A2 oxidation related to IVS1À154C.A. This suggests a potential role of PAH, but also of other aromatic compounds such as HA, in the formation of these adducts. Identification of specific adducts as well as the inclusion of enzymes involved in other metabolic pathways and DNA repair would be needed to better understand the interplay between susceptibility and resistance genes involved in modulating human responses to carcinogenic compounds. 
